Outcome and Failure Analysis of 132 Episodes of Hematogenous Periprosthetic Joint Infections-A Cohort Study.

Renz, Nora; Trampuz, Andrej; Perka, Carsten; Rakow, Anastasia (2022). Outcome and Failure Analysis of 132 Episodes of Hematogenous Periprosthetic Joint Infections-A Cohort Study. Open Forum Infectious Diseases, 9(4), ofac094. Oxford University Press 10.1093/ofid/ofac094

Preview

Text ofac094.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (568kB) | Preview

Background

The outcomes of hematogenous periprosthetic joint infection (PJI) and reasons for failure are largely unknown.

Methods

The outcomes of consecutive patients with hematogenous PJI treated at our institution between 2010 and 2019 were evaluated. Failure was classified as persistence or relapse of infection or new infection. Failure-free survival was assessed using Kaplan-Meier analysis. Proportions between groups were compared with the Fisher exact test.

Results

One hundred thirty-two hematogenous PJI episodes involving knee (n = 76), hip (n = 54), shoulder (n = 1), or elbow (n = 1) prostheses experienced by 110 patients were included. The median follow-up (range) was 20.7 (0.2-89.9) months. Hematogenous PJIs were caused by Staphylococcus aureus (n = 49), Streptococcus spp. (n = 36), Enterococcus faecalis (n = 17), Enterobacterales (n = 16), coagulase-negative staphylococci (n = 9), and other (n = 6). Debridement and implant retention were performed in 50 (38%), prosthesis exchange or removal in 79 (60%), and no surgery in 3 episodes (2%). Treatment failed in 42 episodes (32%), including 6 infection-related deaths. Among 36 nonfatal failures, 21 were caused by a new pathogen and 8 by the same pathogen, in 7 episodes no pathogen was isolated. Of all nonfatal failures, 19 (53%) PJIs were of hematogenous origin. Identification of the primary focus, causative pathogen, and CRIME80 Score did not influence treatment outcome, but the failure rate was higher following prosthesis retention compared with multistage exchange.

Conclusions

Persistence-/relapse-free survival after treatment of hematogenous PJI was high (84%). New hematogenous PJI due to the same or a new pathogen occurred frequently, reducing treatment success to 62% after 4 years of follow-up, suggesting an individual predisposition to hematogenous PJI. The outcome was similar for different pathogens but worse in episodes treated with prosthesis retention compared with multistage exchange.

Interest & Impact

Downloads

97 since deposited on 01 Apr 2022
22 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item